Role of Laghupanchmula in management of Hepatitis-B.

Phytopharmacognostical evaluation and clinical efficacy of Laghupanchmula in Kamala with special reference to Hepatitis B. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/06/054153

Enrollment

Registered

2023-06-20

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K77- Liver disorders in diseases classified elsewhere

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Daignosed case of heaptitis b. 2.patients with HBV DNA quantative 500-2000 IU/ml

Exclusion criteria

Exclusion criteria: 1.Patients who fail to give informed consent 2.Patient with cirrhosis, portal hypertension/ascites, and obstructive jaundice. 3.Pregnant and lactating women. 4.Patient with kidney and heart disease. 5.Patient of Diabetes and Hypertension. 6.Patient infected with Hepatitis A, C, D & Hepatitis E. 7.Mentally unstable . [4:10 pm, 02/05/2023] Anil:

Design outcomes

Primary

Measure	Time frame
Reduction in HBV DNA QuantativeTimepoint: 5 month	—

Secondary

Measure	Time frame
Reduction in SGPT and SGOT level and Bilirubin Timepoint: 1 month	—

Countries

India

Contacts

Public ContactRekha Meena

Institute Of Medical Sciences B.H.U

anilkumar.singh113@gmail.com6394648942

Outcome results